Drug intelligence / Profile preview

linolenic acid + polaprezinc

Development stage
Unknown
Lead developer
Zeria Pharmaceutical
Modality
Peptides, Small Molecules
Administration
Oral
01

Overview

Linolenic acid + polaprezinc is a combination of two active ingredients: linolenic acid, an essential omega-3 polyunsaturated fatty acid, and polaprezinc, a chelated complex of zinc and L-carnosine. Linolenic acid is primarily used for nutritional supplementation to address dietary deficiencies or imbalances in omega-3 fatty acids. It has demonstrated cardiovascular benefits by reducing inflammation, lowering blood pressure, improving endothelial function, and decreasing the risk of arrhythmias and thrombosis[10][8]. Polaprezinc is approved in Japan for the treatment of peptic ulcer disease and dyspepsia; it acts as a mucosal protective agent with antioxidant, anti-inflammatory, and tissue-healing properties[1][6]. The combination may be intended to provide both gastrointestinal protection (from polaprezinc) and systemic anti-inflammatory or nutritional support (from linolenic acid), though no specific branded pharmaceutical product containing both agents was identified in major regulatory databases.

02

Targets

FADS2 (Fatty acid desaturase 2)15-LOX (Lysyl Oxidase)

Beyond the preview

Go deeper on linolenic acid + polaprezinc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on linolenic acid + polaprezinc.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call